FRI0122 Anti-ro/la antibodies and cumulative tissue damage (slicc/acr) in patients with systemic lupus erythematosus

Background Objectives To calculate SLICC/ACR score for a cohort of patients with systemic lupus erythematosus (SLE) and evaluate its relation with the presence of anti-ENA antibodies (U1-RNP, Sm, Ro, and La), anticardiolipin antibodies, and clinical activity at the onset of the disease. Methods We calculated the SLICC scores of 236 patients diagnosed as SLE between 1988 and 2000. Anti-ENA antibodies were studied by ELISA in the first available serum sample of each patient. The SLE disease activity index (SLEDAI) of the first hospital study was calculated retrospectively. Results The mean age of our patients was 39 years (SD 15.8) and the mean duration of disease was 9.7 years (SD 6.9). Eighty-nine percent of the study population were women (211 of 239). Ninety-six patients (40.7%) scored zero, 90 (38.1%) scored 1 or 2, and 50 (21.2%) scored over 2. The main disorders were renal (66; 28%), neuropsychiatric (52; 22%), musculoskeletal (36; 15,3%), and vascular (35; 14.8%). The SLICC score obtained at the last follow-up visit was unrelated to age or the duration of SLE, but it correlated with the initial SLEDAI score (Spearman p Conclusion High SLEDAI score at the onset of SLE and the absence of anti-ENA antibodies, particularly anti-Ro/SS-A or anti-La/SS-B antibodies were associated with significantly higher SLICC scores, suggesting that these factors may indicate poor prognosis in SLE.